1-9 of 9
Sammy Chebon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase III COMMODORE 2 and 1 Trials: Characterization of Breakthrough Hemolysis Events in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab or Eculizumab

Austin G. Kulasekararaj, Jaroslaw Czyz, Catherine Flynn, Gabriela Roncone Gastal, Marek Hus, Chrysavgi Lalayanni, Erfan Nur, Phillip Scheinberg, Yasutaka Ueda, Alessandro Maria Vannucchi, Maria Vidriales Vicente, Iige Viigimaa, Simon Buatois, Alice C. Chang, Sammy Chebon, Alexander Röth
Journal: Blood
Blood (2024) 144 (Supplement 1): 1323.
https://doi.org/10.1182/blood-2024-200400
Published: 2024
Journal Articles

Biomarker Analyses in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab and Eculizumab: Results from the Phase III Randomized COMMODORE 2 Trial

Pontus Lundberg, Silvia de la Iglesia, Richard J Kelly, Austin Kulasekararaj, Jun-Ichi Nishimura, Antonio M Risitano, Alexander Roeth, Simon Buatois, Sammy Chebon, Himika Patel, Anna Kiialainen
Journal: Blood
Blood (2023) 142 (Supplement 1): 4088.
https://doi.org/10.1182/blood-2023-178694
Published: 2023
Journal Articles

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Clinical Trials & Observations
Michael U. Callaghan, Claude Negrier, Ido Paz-Priel, Tiffany Chang, Sammy Chebon, Michaela Lehle, Johnny Mahlangu, Guy Young, Rebecca Kruse-Jarres, Maria Elisa Mancuso, Markus Niggli, Monet Howard, Nives Selak Bienz, Midori Shima, Victor Jiménez-Yuste, Christophe Schmitt, Elina Asikanius, Gallia G. Levy, Steven W. Pipe, Johannes Oldenburg
Journal: Blood
Blood (2021) 137 (16): 2231–2242.
https://doi.org/10.1182/blood.2020009217
Published: 2021
Includes: Supplemental data
Journal Articles

Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)

Michael U. Callaghan, MD, Claude Négrier, Ido Paz-Priel, MD, Tiffany Chang, Sammy Chebon, Michaela Lehle, Johnny Mahlangu, Guy Young, MD, Rebecca Kruse-Jarres, MD, Maria Elisa Mancuso, Markus Niggli, Peter Kuebler, Nives Selak Bienz, Midori Shima, MD, Victor Jimenez-Yuste, MDcal Degree. PhD, Christophe Schmitt, Elina Asikanius, Gallia Levy, Steven W. Pipe, MD, Johannes Oldenburg
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–5.
https://doi.org/10.1182/blood-2020-137438
Published: 2020
Journal Articles

Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study

Michael U. Callaghan, MD, Elina Asikanius, Michaela Lehle, Johannes Oldenburg, Johnny Mahlangu, Marianne Uguen, Sammy Chebon, Rebecca Kruse-Jarres, Victor Jimenez-Yuste, Midori Shima, MD PhD, Peter Trask, Christine L. Kempton, Craig M. Kessler, Gallia G. Levy, Elena Santagostino
Journal: Blood
Blood (2018) 132 (Supplement 1): 383.
https://doi.org/10.1182/blood-2018-99-118160
Published: 2018
Journal Articles

Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies

Victor Jimenez-Yuste, Midori Shima, MD PhD, Ido Paz-Priel, Aric Parnes, Michaela Lehle, Adam Giermasz, Avrita Campinha-Bacote, Markus Niggli, Jerzy Windyga, Sammy Chebon, Peter Trask, Johnny Mahlangu, Steven Pipe, Johannes Oldenburg
Journal: Blood
Blood (2018) 132 (Supplement 1): 1187.
https://doi.org/10.1182/blood-2018-99-118132
Published: 2018
Journal Articles

Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies

Ido Paz-Priel, Tiffany Chang, Elina Asikanius, Sammy Chebon, Thomas Emrich, Elena Fernandez, Peter Kuebler, Christophe Schmitt
Journal: Blood
Blood (2018) 132 (Supplement 1): 633.
https://doi.org/10.1182/blood-2018-99-118492
Published: 2018
Journal Articles

Emicizumab Subcutaneous Dosing Every 4 Weeks for the Management of Hemophilia A: Preliminary Data from the Pharmacokinetic Run-in Cohort of a Multicenter, Open-Label, Phase 3 Study (HAVEN 4)

Victor Jimenez-Yuste, Midori Shima, MDPhD, Katsuyuki Fukutake, Michaela Lehle, Sammy Chebon, Sylvie Retout, Agnès Portron, Gallia G. Levy
Journal: Blood
Blood (2017) 130 (Supplement 1): 86.
https://doi.org/10.1182/blood.V130.Suppl_1.86.86
Published: 2017
Journal Articles

Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-Interventional Study (NIS) from a Real-World Setting

Johannes Oldenburg, Midori Shima, MDPhD, Rebecca Kruse-Jarres, Elena Santagostino, Johnny Mahlangu, Nives Selak Bienz, Sammy Chebon, Elina Asikanius, Gallia G. Levy
Journal: Blood
Blood (2017) 130 (Supplement 1): 1089.
https://doi.org/10.1182/blood.V130.Suppl_1.1089.1089
Published: 2017